Drug intelligence / Profile preview

MAb 012-013

Development stage: Preclinical
Lead developer: MedAbome
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

MAb 012-013 is an investigational, preclinical-stage therapeutic candidate being developed by MedAbome for the treatment of sepsis, inflammatory diseases, and autoimmune diseases. It is designed as both a monoclonal antibody (mAb) and a bispecific antibody (BsAb) targeting two undisclosed biological targets. Developed using MedAbome's proprietary antibody discovery platforms, the candidate is currently in the discovery phase of development.

Beyond the preview

Go deeper on MAb 012-013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAb 012-013.

Explore the full profile